Curemark Announces Four New Sites Participating in Autism Study

News provided by

Dec 02, 2010, 10:25 ET

RYE, N.Y., Dec. 2, 2010 /PRNewswire/ -- Curemark, LLC, (www.curemark.com), a drug research and development company focused on the treatment of neurological diseases, announced that four additional sites across the country are now participating in Phase III clinical trials for the company's autism treatment CM-AT. The new trial sites are:

Institute for Behavioral Medicine, Smyrna, Georgia
Cyn3rgy Research, Gresham, Oregon
Westside Medical Clinic, Clinton, Utah
Oklahoma University Physician's Child Study Center, Oklahoma City

There are now a total of 19 sites nationally conducting Phase III trials for Curemark's autism therapy. The study is targeting a total enrollment of 170 children.

"We have been extremely pleased with the response and the level of participation in the CM-AT autism study," said Dr. Joan Fallon, Curemark founder and CEO. "Enrollment is continuing to proceed well at our other trial sites throughout the country."

CM-AT, which has received Fast Track status from the FDA, targets enzyme deficiencies in autistic children, resulting in an inability to digest protein. The inability to digest protein affects the availability of amino acids, the building blocks of chemicals essential for brain function. If approved, CM-AT will be one of the first therapies to address the underlying physiology of autism.

For information on enrolling in the Curemark CM-AT autism trials, log on to www.clinicaltrials.gov and search "Curemark."

About CUREMARK LLC

Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company's initial products are based upon breakthrough observations by its founder, Dr. Joan Fallon, which revealed a lack of protein digestion in children with autism and ADHD. To learn more about our innovative science, visit www.curemark.com

Safe Harbor Statement

This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of CM-AT, its potential advantages, its potential for use in treating autism, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning CM-AT. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of CM-AT, our ability to finance our development of CM-AT, regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.

SOURCE Curemark LLC